Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Oct 15 2024 | Heart Failure and Cancer: New Insights into a Reciprocal Relationship and Emerging Treatment Approaches HFSA News Press Release Research Statement Read More Oct 4 2024 | BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions Industry News In The News Industry Read More Oct 1 2024 | HFSA and Elsevier Announce New Addition to the Journal of Cardiac Failure Family: JCF-Intersections HFSA News Journal of Cardiac Failure Press Release Read More Oct 1 2024 | Welcoming September's New HFSA Members HFSA News Membership Read More Sep 27 2024 | BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events Industry News In The News Industry Read More Pagination First page « First Previous page ‹ Previous … Page 25 Page 26 Page 27 Page 28 Current page 29 Page 30 Page 31 Page 32 Page 33 … Next page Next › Last page Last »
Oct 15 2024 | Heart Failure and Cancer: New Insights into a Reciprocal Relationship and Emerging Treatment Approaches HFSA News Press Release Research Statement Read More
Oct 4 2024 | BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions Industry News In The News Industry Read More
Oct 1 2024 | HFSA and Elsevier Announce New Addition to the Journal of Cardiac Failure Family: JCF-Intersections HFSA News Journal of Cardiac Failure Press Release Read More
Sep 27 2024 | BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events Industry News In The News Industry Read More
